261 related articles for article (PubMed ID: 17454856)
1. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
[TBL] [Abstract][Full Text] [Related]
2. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
[TBL] [Abstract][Full Text] [Related]
3. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease.
Vespasiani Gentilucci U; Caviglia R; Picardi A; Carotti S; Ribolsi M; Galati G; Petitti T; Afeltra A; Cicala M
Aliment Pharmacol Ther; 2005 May; 21(9):1063-71. PubMed ID: 15854167
[TBL] [Abstract][Full Text] [Related]
4. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.
Katsanos KH; Tsatsoulis A; Christodoulou D; Challa A; Katsaraki A; Tsianos EV
Growth Horm IGF Res; 2001 Dec; 11(6):364-7. PubMed ID: 11914023
[TBL] [Abstract][Full Text] [Related]
5. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease.
Eivindson M; Nielsen JN; Grønbaek H; Flyvbjerg A; Hey H
Horm Res; 2005; 64(1):9-15. PubMed ID: 16088202
[TBL] [Abstract][Full Text] [Related]
7. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
8. Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment.
Grønbek H; Thøgersen T; Frystyk J; Vilstrup H; Flyvbjerg A; Dahlerup JF
Am J Gastroenterol; 2002 Mar; 97(3):673-8. PubMed ID: 11922563
[TBL] [Abstract][Full Text] [Related]
9. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
10. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
[TBL] [Abstract][Full Text] [Related]
11. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25).
López-Bermejo A; Khosravi J; Fernández-Real JM; Hwa V; Pratt KL; Casamitjana R; Garcia-Gil MM; Rosenfeld RG; Ricart W
Diabetes; 2006 Aug; 55(8):2333-9. PubMed ID: 16873698
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal inflammation and the circulating IGF system in humans.
Baricević I; Jones DR; Nikolić JA; Nedić O
Horm Metab Res; 2006 Jan; 38(1):22-7. PubMed ID: 16477536
[TBL] [Abstract][Full Text] [Related]
14. Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?
Axelsson J; Qureshi AR; Divino-Filho JC; Bárány P; Heimbürger O; Lindholm B; Stenvinkel P
Eur J Clin Nutr; 2006 Jun; 60(6):718-26. PubMed ID: 16391585
[TBL] [Abstract][Full Text] [Related]
15. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: effects of twelve-month rhGH treatment.
Ferrante E; Giavoli C; Porretti S; Vassallo E; Ronchi CL; Lania AG; Beck-Peccoz P; Spada A
Horm Metab Res; 2006 May; 38(5):352-5. PubMed ID: 16718634
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease.
Akanji AO; Suresh CG; Al-Radwan R; Fatania HR
Scand J Clin Lab Invest; 2007; 67(5):553-9. PubMed ID: 17763192
[TBL] [Abstract][Full Text] [Related]
18. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
Di Sabatino A; Ciccocioppo R; Benazzato L; Sturniolo GC; Corazza GR
Aliment Pharmacol Ther; 2004 May; 19(9):1019-24. PubMed ID: 15113369
[TBL] [Abstract][Full Text] [Related]
19. Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis.
Lemmey A; Maddison P; Breslin A; Cassar P; Hasso N; McCann R; Whellams E; Holly J
J Rheumatol; 2001 Jan; 28(1):29-34. PubMed ID: 11196538
[TBL] [Abstract][Full Text] [Related]
20. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
